Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

NCT02448641 is registered in ClinicalTrials.gov with SanBio, Inc. as lead sponsor.

NCT NCT02448641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02448641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Lead sponsor
SanBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 8, 2016
Completion date
December 5, 2018
Enrollment
163 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

chronic ischemic stroke